Physician profile
Rafael Lupercio
NPI 1174532618
$7,900.36
in general payments reported to CMS, 2019-2025
38 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what 80% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $830 · 2020: $458 · 2021: $2,185 · 2022: $859 · 2023: $1,119 · 2024: $1,289 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,103 · Travel and Lodging: $248 · Education: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,103.28 |
| Travel and Lodging | $247.81 |
| Education | $217.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,703.22 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| US Endoscopy | $1,092.43 | 2021 | |
| Intuitive Surgical, INC. | $992.36 | 2021-2025 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $730.92 | 2020-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $500.06 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $394.15 | 2023-2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.80 | 2019-2025 | Ofev, Jascayd |
| Merck Sharp & Dohme LLC | $288.45 | 2019-2024 | Winrevair |
| Amgen INC. | $231.22 | 2021-2024 | Tavneos, Tezspire |
| Actelion Pharmaceuticals US, INC. | $210.72 | 2019-2022 | |
| United Therapeutics Corporation | $201.96 | 2019-2022 | |
| Steris Corporation | $163.44 | 2021 | |
| Abbott Laboratories | $147.48 | 2021-2022 | |
| Genentech USA, INC. | $143.90 | 2019-2023 | Xolair |
| Verona Pharma, INC. | $118.32 | 2025 | Ohtuvayre |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veran Medical Technologies, INC. | $103.72 | 2019-2020 | |
| Philips North America LLC | $72.82 | 2024 | (Ak6) Vest Therapy |
| Edwards Lifesciences Corporation | $69.99 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Pfizer INC. | $59.34 | 2024-2025 | |
| Baxter Healthcare | $58.03 | 2025 | Hillrom - Monarch Airway Clearance System |
| Ethicon INC. | $55.81 | 2022 | |
| Abiomed | $47.00 | 2020 | |
| Grifols USA, LLC | $44.84 | 2020-2022 | |
| Electromed, INC. | $42.90 | 2024-2025 | Smartvest |
| Olympus America INC. | $22.57 | 2021 | |
| Pulmonx Corporation | $20.89 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Calliditas Therapeutics US INC. | $20.49 | 2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $18.28 | 2023 | |
| Insmed, INC. | $17.38 | 2025 | Brinsupri |
| Travere Therapeutics, INC. | $9.87 | 2025 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Lupercio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.